Since Aurora kinase A, which is associated with TPX2, is currently tested as a therapeutic target in cancer treatment [18], we investigated whether BRCA2-mutant cancer cells were more sensitive to chemical inhibition of Aurora-A. Here, TPX2 is linked to cancer.